Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Biotech reported its audited financial results for Q4 and FY2024-25, approved by the board on May 29, 2025. Standalone revenue from operations grew 18% year-on-year to Rs. 1,200.1 crore (from Rs. 1,016.9 crore), while profit after tax rose 22% to Rs. 373.0 crore (from Rs. 304.7 crore). Q4 was especially strong, with revenue up 35% YoY to Rs. 429.9 crore and PAT up 46% to Rs. 141.9 crore. Operating cash flow for the year stood at Rs. 244.5 crore, and the board recommended a dividend of Rs. 10.70 per share (face value Re. 1), subject to shareholder approval. BSR & Co. LLP issued an unmodified audit opinion on both standalone and consolidated results, and the company also appointed new secretarial, internal, and cost auditors along with a new company secretary, Ms. Hina Patel, effective May 30, 2025.
Solid double-digit growth in revenue and profits, healthy cash generation, and a steady dividend payout reflect strong operational performance and shareholder-friendly capital allocation, likely to be viewed positively by investors.